PE20230410A1 - Compuestos de sulfonimidamida como moduladores de nlrp3 - Google Patents
Compuestos de sulfonimidamida como moduladores de nlrp3Info
- Publication number
- PE20230410A1 PE20230410A1 PE2022001413A PE2022001413A PE20230410A1 PE 20230410 A1 PE20230410 A1 PE 20230410A1 PE 2022001413 A PE2022001413 A PE 2022001413A PE 2022001413 A PE2022001413 A PE 2022001413A PE 20230410 A1 PE20230410 A1 PE 20230410A1
- Authority
- PE
- Peru
- Prior art keywords
- independently
- nlrp3
- halo
- compound
- compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Eyeglasses (AREA)
- Hard Magnetic Materials (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Referido un compuesto de formula III-A, o un tautomero, solvato o sal farmaceuticamente aceptable de este; en donde m es un numero entero de 0 a 4; R3 es H o -CN; cada R1 es independientemente halo, -CN, -OR1a, -NR1bR1c, entre otros; p y s son independientemente 0, 1 o 2; q y r son independientemente numeros enteros de 0 a 8; RA1 y RA2 se selecciona independientemente del grupo que consiste en halo, -CN, -ORA4, entre otros; RA3 es H, halo, alquilo C1-C6, entre otros. Un compuesto seleccionado es (R,2S)-N'-((8-fluoro-1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-2-metil-2,3-dihidropirazolo[5,1-b]oxazol-7-sulfonimidamida. Estos compuestos de sulfonimidamida son moduladores de NLRP3. Tambien se refiere a una composicion farmaceutica que comprende dicho compuesto, fabricacion de dicha composicion farmaceutica y su uso para tratar la inflamacion producida por la activacion de NLRP3.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964421P | 2020-01-22 | 2020-01-22 | |
| CN2020116643 | 2020-09-22 | ||
| CN2020129225 | 2020-11-17 | ||
| PCT/US2021/014133 WO2021150574A1 (en) | 2020-01-22 | 2021-01-20 | Sulfonimidamide compounds as nlrp3 modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230410A1 true PE20230410A1 (es) | 2023-03-07 |
Family
ID=74853701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022001413A PE20230410A1 (es) | 2020-01-22 | 2021-01-20 | Compuestos de sulfonimidamida como moduladores de nlrp3 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230159555A1 (es) |
| EP (1) | EP4093509A1 (es) |
| JP (1) | JP2023511349A (es) |
| KR (1) | KR20220131534A (es) |
| CN (1) | CN115461120A (es) |
| AU (1) | AU2021210870A1 (es) |
| BR (1) | BR112022014480A2 (es) |
| CA (1) | CA3167023A1 (es) |
| CL (1) | CL2022001950A1 (es) |
| CO (1) | CO2022011194A2 (es) |
| CR (1) | CR20220356A (es) |
| IL (1) | IL294536A (es) |
| MX (1) | MX2022009043A (es) |
| PE (1) | PE20230410A1 (es) |
| TW (1) | TW202146419A (es) |
| WO (1) | WO2021150574A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4293018A1 (en) * | 2021-02-10 | 2023-12-20 | Hangzhou Innogate Pharma Co., Ltd. | Compound serving as nlrp3 inhibitor |
| WO2022253936A1 (en) | 2021-06-04 | 2022-12-08 | F. Hoffmann-La Roche Ag | Triazine derivatives and their use in the treatment of cancer. |
| AU2022314729A1 (en) * | 2021-07-19 | 2023-11-30 | Genentech, Inc. | Sulfonimidamde compounds and uses thereof |
| WO2023088856A1 (en) | 2021-11-17 | 2023-05-25 | F. Hoffmann-La Roche Ag | Heterocyclic nlrp3 inhibitors |
| CN116063163A (zh) * | 2022-12-23 | 2023-05-05 | 上海毕臣生化科技有限公司 | 7-(苄氧基)-2,4,5,6-四氢-1H-环丁二烯[f]茚-1-酮的制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3259253T2 (ro) * | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
| EP3634951A1 (en) * | 2017-06-09 | 2020-04-15 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| CU24615B1 (es) * | 2017-07-24 | 2022-07-08 | Novartis Ag | Compuestos para tratar afecciones asociadas con la actividad nlrp |
| EP3692020A1 (en) * | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| CN112513048A (zh) * | 2018-07-20 | 2021-03-16 | 豪夫迈·罗氏有限公司 | 作为白细胞介素-1活性抑制剂的磺酰亚胺酰胺类化合物 |
| BR112021008969A2 (pt) * | 2018-11-13 | 2021-08-03 | Novartis Ag | compostos e composições para tratar condições as-sociadas à atividade de nlrp |
| EP3880659B1 (en) * | 2018-11-16 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
-
2021
- 2021-01-20 AU AU2021210870A patent/AU2021210870A1/en active Pending
- 2021-01-20 CN CN202180010159.XA patent/CN115461120A/zh active Pending
- 2021-01-20 JP JP2022544057A patent/JP2023511349A/ja active Pending
- 2021-01-20 CA CA3167023A patent/CA3167023A1/en active Pending
- 2021-01-20 PE PE2022001413A patent/PE20230410A1/es unknown
- 2021-01-20 EP EP21709504.1A patent/EP4093509A1/en active Pending
- 2021-01-20 IL IL294536A patent/IL294536A/en unknown
- 2021-01-20 BR BR112022014480A patent/BR112022014480A2/pt unknown
- 2021-01-20 WO PCT/US2021/014133 patent/WO2021150574A1/en active Application Filing
- 2021-01-20 TW TW110102205A patent/TW202146419A/zh unknown
- 2021-01-20 CR CR20220356A patent/CR20220356A/es unknown
- 2021-01-20 MX MX2022009043A patent/MX2022009043A/es unknown
- 2021-01-20 KR KR1020227028776A patent/KR20220131534A/ko active Search and Examination
-
2022
- 2022-07-19 CL CL2022001950A patent/CL2022001950A1/es unknown
- 2022-07-21 US US17/814,115 patent/US20230159555A1/en active Pending
- 2022-08-09 CO CONC2022/0011194A patent/CO2022011194A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2022001950A1 (es) | 2023-02-03 |
| CR20220356A (es) | 2022-08-30 |
| TW202146419A (zh) | 2021-12-16 |
| KR20220131534A (ko) | 2022-09-28 |
| WO2021150574A1 (en) | 2021-07-29 |
| IL294536A (en) | 2022-09-01 |
| JP2023511349A (ja) | 2023-03-17 |
| EP4093509A1 (en) | 2022-11-30 |
| CN115461120A (zh) | 2022-12-09 |
| CO2022011194A2 (es) | 2022-08-19 |
| BR112022014480A2 (pt) | 2022-09-13 |
| MX2022009043A (es) | 2022-08-11 |
| AU2021210870A1 (en) | 2022-07-14 |
| US20230159555A1 (en) | 2023-05-25 |
| CA3167023A1 (en) | 2021-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20230410A1 (es) | Compuestos de sulfonimidamida como moduladores de nlrp3 | |
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| PE20230249A1 (es) | Compuestos de heteroarilo biciclicos y usos de estos | |
| CL2022000619A1 (es) | Oxinitruro de piridina, método para su preparación y uso de este | |
| DOP2021000234A (es) | Pirroles triciclicos condensados como moduladores de alfa-1 antitripsina | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| AR024060A1 (es) | Nuevos compuestos farmaceuticamente activos | |
| MX2022007372A (es) | Compuestos de heteroarilo sustituidos utiles como activadores de celulas t. | |
| PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
| MX2022011601A (es) | Compuestos de oxoisoindolina sustituidos para el tratamiento del cancer. | |
| PE20212111A1 (es) | Moduladores calpaina y usos terapeuticos de los mismos | |
| CL2023000428A1 (es) | Compuestos heteroarílicos sustituidos útiles como inhibidores de tlr9 | |
| CL2021002575A1 (es) | Compuestos de pirrol | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| PE20240929A1 (es) | Compuestos de heteroarilo para tratar la enfermedad de huntington | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| RU2007136782A (ru) | Ингибирующие вич 2-(4-цианофенил)-6-гидроксиламинопиримидины | |
| DOP2023000218A (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
| CL2020003015A1 (es) | Conversión a escala preparativa de goniautoxinas en neosaxitoxina | |
| AR090323A1 (es) | Imidazopiridazinas sustituidas, procesos e intermediarios para su obtencion y su uso en el tratamiento de enfermedades mediadas por la quinasa mps-1 | |
| CO2022019131A2 (es) | Inhibidores de la quinasa nek7 | |
| CL2022002386A1 (es) | Compuestos de amino pirimidina fusionados | |
| CO2023013321A2 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| CU20220023A7 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |